<DOC>
	<DOCNO>NCT00408967</DOCNO>
	<brief_summary>The purpose study determine either two dos EMD 273066 give low dose cyclophosphamide result second time progression long longer first time progression</brief_summary>
	<brief_title>Determine Either 2 Doses Study Drug Given With Low-dose Cyclophosphamide After Complete Partial Response Platinum-based Second-line Therapy Women With Recurrent Ovarian Carcinoma Results Longer Time Progression When Compared First Time Progression .</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Signed write informed consent Age 18 year old Have histologically document ovarian carcinoma ( include primary peritoneal carcinoma ) Have archival tumor tissue available EpCAM expression determination immunohistochemistry Received firstline platinumbased chemotherapy 8 cycle ( approximately 15 24 week ) Experienced complete response firstline platinumbased chemotherapy Experienced platinumfree interval least 6 24 month start end last cycle firstline chemotherapy recurrence Treatment Avastin ( bevacizumab ) permit firstline platinumbased chemotherapy TTP platinumbased reinduction therapy 28 day prior start EMD 273066 Experienced partial complete response 8 cycle secondline platinumbased chemotherapy Have CT/MRI scan within 4 week prior start treatment Be able start cyclophosphamide EMD 273066 treatment within 3 5 week completion secondline chemotherapy KPS ≥70 % No clinical history significantly impair renal function chronic kidney disease . Must estimate glomerular filtration rate ≥50 mL/min determine CockgroftGaultformula WBC count ≥2.5x10³/µL ( total granulocyte ≥1x10³/µL ) Absolute lymphocyte count ( ALC ) ≥0.5x103/µL Platelet count ≥100,000/µL Hemoglobin ( Hgb ) level ≥9 g/dl ALT AST ≤2.5xULN , total bilirubin &lt; 1.5xULN Serum sodium , potassium phosphorus within normal limit Serum amylase within normal limit Serologic test within 4 week prior start study treatment negative result hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) hepatitis B virus ( HBV ) demonstrate negative hepatitis B core antibody ( HBc Ab ) hepatitis B surface antigen ( HbsAg ) Negative pregnancy test willingness use effective contraception study duration 1 month thereafter procreative potential Dyspnea rest , exercise intolerance In subject clinically significant nonmalignant pulmonary disease : Pulmonary function test ( include Forced Vital Capacity [ FVC ] 1second Forced Expiratory Volume [ FEV1 ] ) show &lt; 70 % predict value FVC FEV1 and/or DLCO &lt; 50 % . In subject pulmonary pleural metastatic disease : Arterial oxygen saturation rest measure transcutaneously room air &lt; 90 % increase risk respiratory compromise relate IL2 exposure judgment investigator . ECG evidence clinically significant disease within 4 week prior start study treatment Cardiac stress test ( e.g. , exercise pharmacological thallium test ; exercise pharmacological echocardiography ) abnormal result within 4 week prior start treatment subject history coronary heart disease ( myocardial infarction , angina pectoris pathologic coronary angiography ) Any current evidence congestive heart failure NY Heart Association Grade 2 4 echocardiogram leave ventricular ejection fraction &lt; 45 % sign clinical significant heart disease History repeat clinically relevant episode syncope paroxysmal , ventricular , clinically significant arrhythmias Evidence active brain metastasis Previous malignancy ovarian cancer last 5 year except basal cell cancer skin preinvasive cancer cervix Pregnant lactate female An immediate need palliative radiotherapy systemic corticosteroid therapy Significant active infection Major surgery , chemotherapy , radiation within 21 day start study treatment Received another experimental drug within 28 day start study treatment Uncontrolled hypertension ( systolic ≥180 mmHg diastolic ≥100 mmHg ) hypotension ( systolic ≤90 mmHg ) Presence medically significant third space fluid pleural pericardial effusion edema toxicity grade ≥2 accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Version 3.0 [ 17 ] . Exception allow diseaserelated peritoneal ascites unless patient require frequent repetitive paracentesis management . Previous diagnosis autoimmune disease involve major organ system Transplant recipient immunosuppressive therapy Acute esophageal gastroduodenal ulcer History prior therapy serious uncontrolled medical disorder Investigator 's opinion would impair participation study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Ovarian</keyword>
	<keyword>Cancer</keyword>
	<keyword>Epithelial</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Platinum</keyword>
	<keyword>Second-line therapy</keyword>
	<keyword>Maintenance Therapy</keyword>
	<keyword>Biologic</keyword>
	<keyword>Targeted Therapy</keyword>
	<keyword>Antibody</keyword>
</DOC>